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Methods GFR was measured by inulin clearance (Cin) 
in 50 cancer patients and compared with GFR estimated 
by the CKD–EPI equation, the Japanese equation, and 
Ccr estimated by CGF or measured by 24-h Ccr before 
the first and third cisplatin-containing chemotherapy 
cycles (considered pretreatment and posttreatment, 
respectively).
Results Before treatment, the CKD–EPI and the Japa-
nese equations estimated GFR with higher accuracy than 
Ccr. Posttreatment bias values for GFR estimation using 
the CKD–EPI and the Japanese equations were lower than 
those for Ccr. The CKD–EPI and the Japanese equations 
were also more precise than Ccr. However, for patients 
with low renal function, these equations still overestimated 
Cin.
Conclusion The CKD–EPI and the Japanese equations 
estimated GFR with lower bias and higher precision than 
Ccr pre- and postcisplatin treatment. This study is regis-
tered at UMIN: 000002167.
Keywords Cisplatin · Estimated glomerular filtration 
rate · Inulin clearance · Creatinine clearance · Cancer 
patients
Introduction
Cis-diamminedichloroplatinum(II) (cisplatin) is one of 
the most potent and valuable chemotherapy agents. Since 
its discovery over four decades ago, cisplatin has been 
widely used and has significantly improved the treat-
ment of many malignancies, including head and neck, 
non-small cell lung, small cell lung, germ cell, and many 
other types of cancer [1–3]. However, cisplatin also causes 
adverse events including nausea, vomiting, peripheral 
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However, these equations remain to be evaluated, particu-
larly in cancer patients treated with cisplatin. Therefore, we 
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the GFR in cancer patients treated with cisplatin.
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neuropathy, ototoxicity, and nephrotoxicity [4, 5]. Among 
these, nephrotoxicity is the chief dose-limiting side effect, 
now that emesis can be well controlled by recently devel-
oped antiemetic therapies [6]. The mechanism of cisplatin 
nephrotoxicity is thought to be renal tubular damage by 
uptake into the S3 segment of the proximal tubule through 
the organic cation transporter-2 and the copper transporter 
CTR1 [7–10]. Because nephrotoxicity depends on the 
cumulative dose of cisplatin as well as on the dose per infu-
sion, renal function decreases during repeated courses of 
cisplatin treatment. As urinary excretion is the main path-
way for cisplatin elimination, accurate assessment of renal 
function is important for a safe administration of cisplatin 
and of other chemotherapeutic agents that are excreted in 
the urine [11, 12].
Glomerular filtration rate (GFR) is accepted as the most 
reasonable overall measure of renal function [13] and can 
be precisely assessed using filtration markers as inulin, 
125I-iothalamate, 51Cr-ethylenediaminetetraacetic acid 
(51Cr-EDTA), or iohexol [13]. However, these techniques 
for the direct measurement of renal function are complex, 
expensive, time- and effort-consuming, and difficult to be 
performed in routine clinical practice or clinical trials of 
cancer chemotherapy. Instead, creatinine clearance (Ccr), 
measured using 24-h urine collection (24-h Ccr), or the 
Cockcroft–Gault formula (CGF), developed to estimate 
24-h Ccr, has been used in daily practice and clinical trials 
[14]. However, assessment of renal function by Ccr over-
estimates GFR because creatinine is partly excreted via 
tubular secretion in addition to glomerular filtration in the 
kidney [15–18]; especially, when we apply these estimates 
using creatinine to cancer patients, it is important to note 
that creatinine production is influenced by muscle mass, 
nutritional state, and inflammation, which are often altered 
in cancer patients [13, 19–21]. Furthermore, it was reported 
that nephrotoxic anticancer agents, such as cisplatin, may 
alter the correlation between GFR and Ccr [22].
Daugaard et al. [22] suggested that Ccr was not suit-
able to measure renal function during high-dose cisplatin 
treatment (40 mg/m2 daily for 5 days) for germ cell tumors. 
After cisplatin administration, there was no correlation 
between GFR measured by 51Cr-EDTA and 24-h Ccr up to 
3 months after the last dose of cisplatin because of progres-
sive muscle wasting and tubular disorders caused by the 
drug. Therefore, although clinical trial protocols and empir-
ical guidelines often require a normal Ccr for the admin-
istration of the full dose of cisplatin, it is unclear whether 
Ccr is a surrogate of GFR after administration of this drug, 
especially at a regular dose (70–100 mg/m2), which is 
widely used in chemotherapy in many cancers.
Recently, for better estimation of renal function in 
daily medical practice, the Chronic Kidney Disease 
Epidemiology Collaboration (CKD–EPI) equation has been 
developed from GFR measured by iothalamate [23] and 
is commonly used in the USA and Europe. Similarly, the 
equation derived from GFR measured by inulin clearance 
(Cin), namely the Japanese equation for estimated GFR 
(the Japanese equation), has been developed in Japan [24]. 
These equations for GFR estimation are more accurate than 
Ccr [24], and they have been widely accepted in medical 
practice. It is important to recognize that these equations 
were mainly developed in patients with chronic kidney 
disease (CKD), and cancer patients were not included in 
these populations. Furthermore, these equations also utilize 
creatinine, whose production is altered in cancer patients. 
Therefore, it is unclear whether these equations do accu-
rately predict GFR in cancer patients. It is necessary to 
evaluate their validity for the estimation of renal function 
in cancer patients before they are implemented in oncol-
ogy practice or clinical trials of cancer chemotherapy. Most 
importantly, the validity of these equations for the estima-
tion of GFR in cancer patients during and after cisplatin 
treatment needs to be evaluated.
In the present study, to determine the most precise 
method for the estimation of GFR in cancer patients treated 
with cisplatin, we have prospectively assessed GFR by 
measuring Cin in Japanese cancer patients before the first 
and third cycles of chemotherapy containing cisplatin and 
compared Cin with GFR estimated using the CKD–EPI 
equation, the Japanese equation, CGF, and 24-h Ccr.
Patients and methods
Patient population
We investigated Cin in cancer patients hospitalized at the 
Kobe University Hospital receiving cisplatin-containing 
chemotherapy. Eligible patients (1) had histologically or 
cytologically confirmed cancer, (2) were scheduled to 
receive 70–100 mg/m2 of cisplatin (single dose), (3) had 
an expected survival of more than 3 months, (4) had ade-
quate bone marrow and liver functions, (5) had the Japa-
nese equation ≥50 mL/min/1.73 m2, and (6) had an Eastern 
Cooperative Oncology Group (ECOG) performance status 
of 0–1. Exclusion criteria were (1) concomitant medica-
tions, such as vitamin E or probucol, whose antioxidant 
activity affects the measurement of inulin levels, (2) con-
traindications to inulin, and (3) history of cisplatin admin-
istration within the previous 6 months. This study was per-
formed in compliance with the Helsinki Declaration. All 
patients gave written informed consent to participate in 
this study, which was approved by the Institutional Review 
Board of the Kobe University Hospital.
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Evaluation of renal function
All estimations of renal function were performed within 
7 days before the first and third cycles of cisplatin-contain-
ing chemotherapy. We measured Cin in the morning after 
overnight fasting, and serum and 24-hour urine samples for 
24-h Ccr were obtained on the same day. We excluded from 
the analysis patients who did not collect all urine. Serum 
creatinine and inulin were measured by autoanalyzer using 
enzymatic methods. Cin was calculated from three sets of 
serum and urine inulin concentrations as well as urine vol-
umes. Inulin was dissolved in physiological saline at a con-
centration of 1 % and infused intravenously over 2 h. The 
rate of infusion was 300 mL/h for the first 30 min and then 
100 mL/h for the following 90 min. For the measurement of 
inulin concentrations, serum samples were collected at 45, 
75, and 105 min into the infusion of inulin. After patients 
completely emptied the bladder at 30 min, urine samples 
were collected between 30 and 60 min, between 60 and 
90 min, and between 90 and 120 min. GFR was predicted 
in each patient using the following formulae:
where Scr is serum creatinine level. κ = 0.7 (0.9 if male), 
α = −0.329 (−0.411 if male), min = the minimum of 
Scr/κ or 1, max = the maximum of Scr/κ or 1.
The CKD–EPI equation was adjusted for Japanese 
patients by multiplying by 0.813 [25].
Because the CKD–EPI and the Japanese equations esti-
mate GFR adjusted for BSA, they were used after back-
calculation to absolute values when correlation to Cin was 
investigated.
where Scr is serum creatinine, BSA is body surface area, 


















(×1.018 if female) × 0.813
Japanese estimation (mL/min) [24]











Ucr × volume of 24-h urine collection
Scr× 1440
Statistical analysis
All data were expressed as mean ± standard deviation 
(SD). A paired t test was used to investigate the statistical 
significance of differences between Cin and the CKD–EPI 
equation, the Japanese equation, CGF, and 24-h Ccr. p val-
ues <0.05 were considered to be statistically significant. 
Performance of the prediction of Cin by each formula was 
evaluated for bias and precision. Bias, a measure of sys-
tematic error, was expressed as both mean prediction error 
(ME) and mean percentage error (MPE); precision was 
shown as root-mean square error (RMSE), which was cal-
culated as the square root of the sum of the squared error/n, 
where n is the sample size. The accuracy of prediction of 
the GFR by each formula relative to the Cin was expressed 
as percentage of the samples within 30 % of observed Cin.
Data from 50 patients were analyzed in this study. 
Assuming an α error of 0.05, a power of 90, and 30 % coef-
ficient of variation for Cin and estimations of GFR by each 
formula, a sample size of 45 would detect a difference of 
15 % between Cin and each estimate, which was consid-
ered clinically meaningful. IBM® SPSS Statistics, version 
19, was used to calculate statistical significance.
Results
To obtain two data sets (pretreatment and posttreatment 
data) from 50 patients, 75 cancer patients who were sched-
uled to receive cisplatin-containing chemotherapy were 
enrolled in this study from July 2009 to December 2012 
at the Kobe University Hospital. The two data sets could 
not be obtained from 25 patients because of discontinuation 
of cisplatin administration in seven (severe renal damage 
in two, other side effects in three and progressive disease 
in two), withdrawing consent in seven, technical errors in 
four, and difficulty in urine excretion in seven. The major-
ity of the tumors were head and neck cancer (58 %), fol-
lowed by esophageal (26 %) and lung (8 %) cancers 
(Table 1). On average, the total dose of cisplatin until the 
second measurement of renal function was 154 ± 19.2 mg/
m2 (Table 1). None of the patients received other nephro-
toxic drugs. The mean estimated GFRs by each method are 
shown in Table 2.
Pretreatment
Estimated values of GFR by the CKD–EPI and the Japanese 
equations were similar to Cin, but 24-h Ccr significantly 
overestimated renal function compared with Cin (Table 2). 
Bias (ME and MPE) of the CKD–EPI (−3.96 mL/min 
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and −1.77 %) and the Japanese equations (−2.36 and 
−0.85 %) were approximately equal and smaller than 
CGF (5.38 mL/min and 8.61 %, p < 0.0001) and 24-h Ccr 
(26.4 mL/min and 36.1 %, p < 0.0001) (Table 3). When we 
compared precision (RSME) for the estimation of pretreat-
ment Cin using the different approaches, the CKD–EPI and 
the Japanese equations were approximately equal (15.7 and 
15.5 mL/min) and were more precise than CGF and 24-h 
Ccr (20.9 and 36.7 mL/min) (Table 3). Both the CKD–EPI 
and the Japanese equations were the most accurate for 
predicting GFR, with 92 % of the samples within 30 % of 
GFR (Table 3). When scatter plots of Cin against the other 
Table 1  Patients’ 
characteristics (n = 50)
Mean ± standard deviation (range)
BSA body surface area, BMI body mass index, PS performance status, CDDP cisplatin, RT radiation, 5-FU 
fluorouracil, DTX docetaxel
a The number of patients requiring medication
Pretreatment Posttreatment
Sex (female, male) 16, 34
Age (years), median (range) 64 (31–87) 64 (31–87)
Weight (kg) 56.0 ± 10.3 (32.6–78.8) 54.1 ± 10.1 (30.3–
81.0)
BSA (m2) 1.59 ± 0.17 (1.19–1.98) 1.57 ± 0.17 (1.15–
1.99)
BMI (kg/m2) 21.0 ± 2.87 (14.7–27.5) 20.3 ± 2.84 (13.7–
27.0)
PS (0, 1, 2) 16, 34, 0 11, 33, 6
Cancer type





CDDP + RT 17
CDDP + 5-FU + RT 7
CDDP + DTX 7
CDDP + DTX + 5-FU 6
CDDP + 5-FU 5
Others 8




Table 2  Renal function 
(n = 50)
Mean ± standard deviation (range)
Cin inulin clearance, CKD–EPI Chronic Kidney Disease Epidemiology Collaboration, CGF Cockcroft–
Gault formula, 24-h Ccr creatinine clearance from 24-h urine collection
* p < 0.05 versus Cin
Pretreatment Posttreatment
Cin (mL/min) 76.7 ± 19.7 (35.6–142.3) 59.5 ± 22.1 (17.2–108.0)
The CKD–EPI equation (mL/min) 72.7 ± 12.5 (44.4–110.7) 66.7* ± 14.4 (30.6–111.3)
The Japanese equation (mL/min) 74.3 ± 17.3 (39.1–118.1) 66.0* ± 19.4 (30.9–132.4)
CGF (mL/min) 82.0 ± 25.5 (39.5–161.0) 72.4* ± 27.8 (30.2–176.1)
24-h Ccr (mL/min) 103.1* ± 32.8 (49.3–240.7) 78.8* ± 28.3 (23.7–153.6)
Serum creatinine (mg/dL) 0.72 ± 0.14 (0.44–1.00) 0.81 ± 0.21 (0.39–1.63)
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estimates were investigated before treatment, the CKD–EPI 
and the Japanese equations showed relatively good correla-
tions even in cancer patients (Fig. 1a, b, left), whereas CGF 
and 24-h Ccr overestimated Cin in many patients (Fig. 1c, 
d, left).
Posttreatment
Weight, body mass index (BMI), and BSA in the two cycles 
of treatment were significantly lower than the respective 
pretreatment values (p < 0.05) (Table 1). Compared with 
pretreatment, posttreatment Cin significantly decreased 
from 76.7 ± 19.7 to 59.5 ± 22.1 mL/min (p < 0.05) 
(Table 2). Consistent with this decrease in Cin, serum cre-
atinine was significantly increased after cisplatin treatment 
(0.72 ± 0.14 vs. 0.81 ± 0.21 mg/dL, p < 0.05) (Table 2).
After two cycles of chemotherapy with cisplatin, bias 
(ME and MPE) of the CKD–EPI (7.22 mL/min and 22.2 %) 
and of the Japanese equations (6.52 mL/min and 19.1 %) 
were approximately equal and smaller than CGF (12.9 mL/
min and 27.4 %, p < 0.05) and 24-h Ccr (19.3 mL/min and 
39.8 %, p < 0.0005) (Table 3). Similarly to the pretreat-
ment, precision (RMSE) values of the posttreatment CKD–
EPI (15.6 mL/min) and Japanese equations (15.8 mL/min) 
were also approximately equal and more precise than CGF 
(21.8 mL/min) and 24-h Ccr (26.6 mL/min) (Table 3). In 
the scatter diagram of the posttreatment values, CGF and 
24-h Ccr overestimated Cin in most patients, as during pre-
treatment (Fig. 1c, d). In contrast, the CKD–EPI and the 
Japanese equations did not overestimate Cin, when Cin 
was normal. However, these equations also tended to over-
estimate Cin especially at decreased Cin levels (Fig. 1a, b, 
right). Accordingly, in patients with lower Cin (<50 mL/
min), higher bias and lower precision values were obtained 
compared with patients with normal renal function (Cin 
≥50 mL/min) (Table 4). Consequently, even if patients 
had a CKD–EPI equation value ≥60 mL/min, 26 % (9/35) 
of them had decreased renal function (Cin <50 mL/min). 
Similarly, 23 % (7/30) of the patients with a Japanese equa-
tion value ≥60 mL/min had a Cin <50 mL/min.
Discussion
The evaluation of renal function in cancer patients is 
important for a safe chemotherapy. Renal function is 
always included in eligibility criteria for clinical trials, 
and it is repeatedly monitored during chemotherapy that 
includes nephrotoxic drugs such as cisplatin. However, 
it is unclear whether equations based on creatinine levels 
can be used as surrogates for GFR in cancer patients whose 
creatinine production has been altered by the disease. Fur-
thermore, Ccr is not correlated with GFR after high-dose 
cisplatin administration [22]. Although the CKD–EPI 
and the Japanese equations are currently used as better 
estimates of GFR than Ccr, they were mostly developed 
in CKD patients without cancer. In the present study, we 
evaluated renal function in cancer patients before and after 
the administration of cisplatin. We found that 24-h Ccr and 
CGF overestimated GFR measured by Cin, regardless of 
cisplatin administration (Table 3; Fig. 1), probably because 
approximately 20 % of creatinine is cleared into the urine 
by proximal tubular secretion [15–17]. On the other hand, 
the CKD–EPI and the Japanese equations accurately esti-
mated GFR even in cancer patients before cisplatin admin-
istration (Table 3; Fig. 1). These results are consistent with 
our previous report [26]. Furthermore, the new estimation 
methods, the CKD–EPI, and the Japanese equations pre-
dicted GFR with lower bias (ME and MEP) and greater 
precision (RMSE) than Ccr, not only before but also after 
cisplatin treatment (Table 3). Therefore, we recommend to 
replace Ccr with these new equations in cisplatin-contain-
ing chemotherapy. However, these equations tend to over-
estimate Cin in patients with low Cin levels after cisplatin 
administration (Table 4; Fig. 1). Even when patients appear 
to have good renal function (≥60 mL/min) according to the 
Table 3  Bias and precision of prediction for Cin by each estimate
ME mean prediction error, MPE mean percentage error, RMSE root-mean square error, CKD–EPI Chronic Kidney Disease Epidemiology Col-
laboration, CGF Cockcroft–Gault formula, 24-h Ccr creatinine clearance from 24-h urine collection
Pretreatment Posttreatment










−3.96 −1.77 15.7 92 7.22 22.2 15.6 60
The Japanese 
equation
−2.36 −0.85 15.5 92 6.52 19.1 15.8 68
CGF 5.38 8.61 20.9 78 12.9 27.4 21.8 56
24-h Ccr 26.4 36.1 36.7 42 19.3 39.8 26.6 50
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Fig. 1  Relationship between 
inulin clearance (Cin) and a 
the Chronic Kidney Disease 
Epidemiology Collaboration 
(CKD–EPI) equation, b the 
Japanese glomerular filtration 
rate estimation equation (the 
Japanese equation), c the Cock-
croft–Gault formula (CGF), 
and d creatinine clearance from 
24-h urine collection (24-h 
Ccr). Black lines show the line 
of identity
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CKD–EPI or the Japanese equations, qualifying them for a 
repeated dose of cisplatin, approximately 25 % of them in 
fact have renal dysfunction (Cin <50 mL/min), thus requir-
ing a reduction in the dose.
The best method for the estimation of renal function dur-
ing treatment with nephrotoxic drugs such as cisplatin is con-
troversial. While a significant decrease in measured GFR by 
51Cr-EDTA has been observed after cisplatin treatment [22, 
27, 28], serum creatinine and Ccr have not been reported to 
change in several studies [22, 29–31]. Among these reports, 
Daugaard et al. [22] noted that 24-h Ccr no longer correlated 
with 51Cr-EDTA clearance after high-dose cisplatin treatment. 
However, our study showed that Cin and 24-h Ccr correlated 
even after cisplatin treatment, although 24-h Ccr consistently 
overestimated Cin. First, the discrepancy between the two 
studies may be due to differences in the dose of cisplatin. In 
the previous report, a high dose of cisplatin (40 mg/m2 daily 
for 5 days) was used, whereas in our study we treated patients 
with moderate doses (70–100 mg/m2 as a single infusion), 
widely used in many cancers. Second, severe malnutrition 
leading to muscular atrophy might be responsible for the poor 
correlation in the previous study. Indeed, patients suffered 
from severe weight loss (an average of 10.35 ± 1.04 kg) dur-
ing three cycles of chemotherapy [22]. In contrast, weight loss 
was small in our study, probably due not only to the lower 
doses of cisplatin but also to advances in antiemetic therapy. 
In our study, all patients received 5-hydroxytryptamine recep-
tor antagonist or neurokinin 1 receptor antagonist [32], which 
were not available at the time of the previous study. Third, 
the number of patients in the previous study was small: renal 
function was evaluated after treatment in only 16 patients.
We revealed that the CKD–EPI equation and the Japa-
nese equations estimate renal function more accurately 
than Ccr in cancer patients. However, chemotherapeutic 
regimens currently used in daily practice were established 
in clinical studies in the past when the new methods were 
not available, and we may not have to change daily prac-
tice for such regimens as long as toxicities of drugs that are 
excreted via the kidneys are at the expected levels. There-
fore, further prospective studies are necessary to assess the 
efficacy and safety of cisplatin administration by using the 
new equations. Furthermore, we would like to propose to 
replace Ccr with the new equations to evaluate renal func-
tion in future clinical studies for developing new agents. 
Additionally, because other chemotherapeutic agents, 
including carboplatin and etoposide, are excreted in urine, 
dosing guidance should be evaluated by using the new 
equations.
In conclusion, lower bias and higher precision val-
ues were obtained using the CKD–EPI and the Japanese 
equations than using CGF and 24-h Ccr in cancer patients 
before and after chemotherapy with cisplatin. Therefore, it 
is recommended to use these new equations instead of Ccr 
for the evaluation of renal function when cisplatin-contain-
ing chemotherapy is used; however, it is important to note 
overestimate renal function in patients with low Cin.
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